Semaglutide therapy for metabolic dysfunction–associated steatohepatitis: November 2025 updates to AASLD Practice Guidance

医学 肝硬化 非酒精性脂肪肝 内科学 脂肪变性 临时的 临床实习 脂肪肝 肝纤维化 纤维化 重症监护医学 肝病 阶段(地层学) 外科 疾病 肝纤维化 赛马鲁肽 胃肠病学 药方 临床试验 肝移植 梅德林
作者
Meena B. Bansal,Heather M. Patton,Timothy R.M. Morgan,Rotonya M. Carr,Jonathan A. Dranoff,Alina M. Allen
出处
期刊:Hepatology [Lippincott Williams & Wilkins]
卷期号:83 (5): 1326-1340 被引量:191
标识
DOI:10.1097/hep.0000000000001608
摘要

This practice recommendation serves as an update to the 2023 AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease (NAFLD), now known as metabolic dysfunction-associated steatotic liver disease (MASLD), and provides implementable guidance on patient selection for treatment, consideration of comorbidities, and monitoring of treatment safety and efficacy of semaglutide. FDA-indication and Practice Recommendation: The Wegovy formulation, whose main ingredient is semaglutide, received accelerated FDA approval in August 2025 for treating MASH with moderate-to-advanced fibrosis (consistent with stages F2-F3 fibrosis), based on interim results of the phase 3 ESSENCE trial where 72 weeks of 2.4 mg/week subcutaneous injection resulted in achievement of both primary histologic endpoints: (1) resolution of MASH without worsening of fibrosis (62.9% vs. 34.3% placebo, p <0.001) and (2) ≥1 stage reduction in liver fibrosis without worsening of MASH (36.8% vs. 22.4% placebo, p <0.001); final approval awaits long-term outcomes. Patient Selection: Candidates should have MASH with stage 2-3 fibrosis, identified using non-invasive tests (NITs) such as VCTE (8-15 kPa), MRE (3.1-4.4 kPa), or ELF (9.2-10.5), rather than liver biopsy, which is impractical and unnecessary for most patients. In those with VCTE (15-20 kPa), MRE (4.4-5 kPa), or ELF (10.5-11.3), an individualized decision to treat should be based on exclusion of cirrhosis with another confirmatory NIT, or cross-sectional imaging excluding nodular-appearing liver contour and signs of portal hypertension, or a platelet count of <150,000/mm 3 . While semaglutide is not approved to treat patients with MASH cirrhosis (VCTE >20 kPa, MRE>5.0 kPa, ELF>11.3, and/or evidence of portal hypertension), those with compensated cirrhosis who are receiving semaglutide for another FDA-approved indication should be monitored carefully. Monitoring and Safety: Semaglutide showed a favorable hepatic safety profile in the ESSENCE trial, with no discontinuations due to liver enzyme elevations. Routine hepatic panels are recommended only as clinically indicated. The most common adverse events were gastrointestinal (nausea, diarrhea, constipation, vomiting), generally mild and transient; patient education and dose titration help improve tolerance. Clinicians should monitor for rare but serious risks, including acute kidney injury (from dehydration), symptomatic gallbladder disease, pancreatitis, thyroid C-cell tumors, retinopathy progression, and lean mass loss. Treatment Response and Concomitant Therapy: Lifestyle modification remains the cornerstone of MASLD/MASH management alongside semaglutide. Combination use of resmetirom with semaglutide 2.4mg/week has not been studied. While no NITs reliably predict histologic response at the individual patient level, reductions from baseline to 72 weeks of treatment suggest significant improvement in MASH resolution (ALT ≥17 U/L or ≥20%) and fibrosis improvement (VCTE LSM ≥30%; MRE LSM ≥20%; ELF ≥0.5). Non-response may be suspected if ALT or NITs worsen. The benefit is uncertain if a suboptimal response occurs, and may require an individualized approach and further follow-up.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Skyler完成签到 ,获得积分10
刚刚
xucc发布了新的文献求助50
1秒前
吾吾发布了新的文献求助30
1秒前
1秒前
xing完成签到,获得积分10
1秒前
研友_LwlNdn的应助被老帅比采纳,获得10
2秒前
科研通AI2S的应助被老帅比采纳,获得10
2秒前
2秒前
2秒前
fgl完成签到,获得积分10
2秒前
强健的冰之完成签到,获得积分10
2秒前
宋沅鸿关注了科研通微信公众号
2秒前
destiny完成签到,获得积分10
2秒前
franklove发布了新的文献求助10
3秒前
少国完成签到,获得积分10
3秒前
於傲松发布了新的文献求助10
3秒前
小二郎的应助被小郭采纳,获得10
4秒前
小李子完成签到,获得积分10
4秒前
Cc发布了新的文献求助10
4秒前
彭于晏的应助被一铺研究区采纳,获得10
4秒前
nana完成签到,获得积分10
4秒前
5秒前
刘哈哈完成签到,获得积分10
5秒前
小杨完成签到,获得积分20
5秒前
Assam完成签到,获得积分10
5秒前
5秒前
传奇3的应助被千寻采纳,获得10
5秒前
5秒前
重要莹发布了新的文献求助10
6秒前
STEAM发布了新的文献求助10
6秒前
6秒前
邹馥罄完成签到 ,获得积分10
6秒前
JamesPei的应助被听话的馒头采纳,获得10
7秒前
orixero的应助被Zara采纳,获得10
7秒前
kyxiaocui完成签到,获得积分10
8秒前
乐乐的应助被mkl采纳,获得10
8秒前
江荻完成签到 ,获得积分10
8秒前
含糊的水卉完成签到,获得积分10
8秒前
冷傲的绿蓉完成签到,获得积分10
8秒前
zgw发布了新的文献求助10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180488
求助须知:如何正确求助?哪些是违规求助? 9570485
关于积分的说明 21812623
捐赠科研通 7776592
什么是DOI,文献DOI怎么找? 3433286
关于科研通互助平台的介绍 2557522
邀请新用户注册赠送积分活动 2479162